Borneol

Borneol at a Glance

Borneol is a bicyclic monoterpene alcohol — camphor with the ketone reduced to an alcohol, and much of camphor’s cooling, woody, medicinal smell. It takes its name from Borneo, where the resin of Dryobalanops aromatica was harvested and traded as “Borneo camphor” long before European chemistry named the molecule.

In Chinese medicine it is bingpian, a near-pure single chemical rather than a plant extract, used topically for pain for centuries. That long use finally met a controlled trial in 2017: in 122 patients with postoperative pain, randomised and double-blind, topical borneol relieved pain significantly better than placebo, and mouse work in the same paper identified TRPM8 — the cold receptor — as the target through which it works ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}.

Its second literature is about a different problem entirely. Borneol is the classic Chinese “messenger” or envoy herb, added to formulae to carry the other ingredients where they need to go, and modern work supports a version of that: a systematic review and meta-analysis of 58 animal studies found that co-administering borneol increased central nervous system drug concentrations in 45 of 47 studies that measured them ^{2Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →}.

That envoy logic has since been tested at scale in people. Edaravone dexborneol is a licensed stroke drug that is simply edaravone plus (+)-borneol, and in a 1,165-patient phase III trial the only difference between the two arms was the borneol — which is as clean a read on one plant constituent as human medicine offers ^{15Reference 15Xu J et al. · 2021RCTEdaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial — randomised controlled trialView study →}.

Chirality: Three Borneols, Not One

Borneol is sold and studied in three configurational forms, and the distinction is not cosmetic — plant origin, price and pharmacology all track it ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}.

• d-Borneol ((+)-borneol) — the form in the resin of Dryobalanops aromatica and in the oil of the rare Cinnamomum camphora borneol variant, a Chinese camphor-tree cultivar rich enough in it to be nicknamed “plant gold” ^{10Reference 10Huang SQ et al. · 2024ReviewHuang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/View study →}. This is the material of the classical bingpian trade.
• l-Borneol ((−)-borneol) — obtained from Blumea balsamifera and traded separately.
• Synthetic dl-borneol — a racemate made by chemical transformation of camphor or turpentine oil, and the cheapest of the three. Its characteristic impurity is isoborneol, the exo epimer, which is where quality-assessment work concentrates ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}.

The forms are not interchangeable. When d-, l- and synthetic borneol were compared head-to-head as absorption enhancers for Panax notoginseng saponins in rats, all three promoted exposure, but the synthetic racemate worked only at a 1:1 ratio with the saponins, while the natural isomers were effective more broadly ^{8Reference 8Mei Y et al. · 2024AnimalBorneol acts as an adjuvant agent to enhance the oral absorption of Panax notoginseng saponins in rats: effect of optical configuration and compatibility ratios — animalView study →}. A study, a formula or a supplement that says only “borneol” has left out something load-bearing.

Borneol as a Delivery Agent

The idea that borneol carries other drugs into the brain began as a traditional-medicine doctrine and has accumulated an unusually large preclinical evidence base.

A systematic review and meta-analysis of 58 studies, 63 comparisons and 1,137 animals found that among 47 studies measuring central nervous system drug concentration, 45 showed a significant increase with borneol co-administration and 2 showed no difference. Nineteen comparisons measured blood–brain barrier permeability directly — by Evans blue extravasation, rhodamine 123 accumulation, imaging-agent content and barrier ultrastructure — and found it increased ^{2Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →}. The mechanisms implicated are efflux-transporter inhibition, loosening of tight-junction proteins, increased vasodilatory neurotransmitter release, and inhibition of ion-channel-driven active transport ^{2,3Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →Reference 3Zhang QL et al. · 2017Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeabilityView study →}.

Two details matter for reading this literature honestly. First, the effect appears reversible and reasonably selective: six of the seven studies reporting safety found borneol did not raise the co-administered drug’s concentration in peripheral tissues ^{2Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →}, which is what you would want from a targeting agent rather than a general absorption enhancer. Second, all of it is animal work. No human trial has tested borneol as a blood–brain-barrier adjuvant, and the meta-analysis is explicitly preclinical.

The same property is used outside the brain. Borneol enhances the oral absorption of poorly bioavailable saponins ^{8Reference 8Mei Y et al. · 2024AnimalBorneol acts as an adjuvant agent to enhance the oral absorption of Panax notoginseng saponins in rats: effect of optical configuration and compatibility ratios — animalView study →} and is being investigated as a permeation enhancer across several physiological barriers ^{4Reference 4Kulkarni M et al. · 2021ReviewBorneol: a promising monoterpenoid in enhancing drug delivery across various physiological barriers — reviewView study →}.

What It's Used For

Borneol’s evidence base is lopsided in an unusual direction: one good human trial for one narrow indication, and a very large animal literature for a property that is not a therapy at all.

Evidence by IndicationStrength of support · Beta

01Topical AnalgesiaPromising68%Randomised, double-blind, placebo-controlled trial in 122 postoperative-pain patients plus a defined TRPM8 mechanism ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}

02Neuroprotection In Acute StrokePromising62%Phase III trial in 1,165 patients where (+)-borneol was the only variable between arms; licensed combination product ^{15Reference 15Xu J et al. · 2021RCTEdaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial — randomised controlled trialView study →}

03Blood-Brain Barrier OpeningPromising52%Meta-analysis of 58 animal studies / 1,137 animals; consistent, reversible, mechanistically characterised — but no human data ^{2,3,4Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →Reference 3Zhang QL et al. · 2017Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeabilityView study →Reference 4Kulkarni M et al. · 2021ReviewBorneol: a promising monoterpenoid in enhancing drug delivery across various physiological barriers — reviewView study →}

04Anti-InflammatoryShaky30%Human gingival fibroblasts: borneol among four volatiles suppressing IL-6 and IL-8 release ^{13Reference 13Ehrnhöfer-Ressler MM et al. · 2013In vitroIdentification of 1,8-cineole, borneol, camphor, and thujone as anti-inflammatory compounds in a Salvia officinalis L. infusion using human gingival fibroblasts — in vitroView study →}; supporting review-level animal work ^{6Reference 6Hu X et al. · 2024Systematic reviewAdvances and perspectives on pharmacological activities and mechanisms of the monoterpene borneol — systematic reviewView study →}

05Cardio-Cerebrovascular ProtectionShaky24%Review-level animal and mechanistic work; in clinical use borneol is a minor component of compound formulae, never the tested agent ^{7,14Reference 7Liu S et al. · 2021ReviewBorneol in cardio-cerebrovascular diseases: pharmacological actions, mechanisms, and therapeutics — reviewView study →Reference 14Luo J et al. · 2015Systematic reviewCompound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews — systematic reviewView study →}

Mechanisms

Borneol and menthol share TRPM8 and diverge after it — the 2017 trial went out of its way to show the two analgesias are mechanistically distinct, which is unusual and useful information for a molecule that is otherwise easy to file as “camphor-like”.

Pharmacokinetics

Borneol is small, lipophilic and volatile, which is the whole basis of its delivery behaviour: it crosses membranes readily and takes advantage of that to modify how other molecules cross. A validated LC-MS/MS method for (+)-borneol in rat plasma has been used for pharmacokinetic study ^{9Reference 9Ren J et al. · 2019AnimalDevelopment and validation an LC-MS/MS method to quantify (+)-borneol in rat plasma: application to a pharmacokinetic study — animalView study →}, and the configurational forms differ in their kinetics ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}. No human pharmacokinetic dataset is established — no oral bioavailability figure, no half-life, no clearance route characterised in people. Given that its principal proposed use is as a co-administered adjuvant, that absence is the central gap in the literature.

Clinical Trials

Last checked: September 2026.

Isolate vs. Plant Studies

Borneol is one of the few aromatic constituents where the isolate is the traditional material. Bingpian is not an extract with borneol in it — it is borneol, at high purity, which is why the 2017 trial could test a centuries-old preparation and a pure chemical at the same time ^{1,5Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}.

That makes the usual caveat run backwards here. The isolate evidence is the good evidence. Both human trials used pure borneol — one topically against placebo ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}, one as the single added ingredient in a two-drug comparison ^{15Reference 15Xu J et al. · 2021RCTEdaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial — randomised controlled trialView study →} — and the second is the rarer design: an add-on trial is the only way to attribute an effect to one constituent inside a combination, and it is exactly what the formula-level literature normally fails to do. The weaker material is that formula-level work, where borneol is one ingredient among several and nothing can be attributed to it ^{14Reference 14Luo J et al. · 2015Systematic reviewCompound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews — systematic reviewView study →}. And the plant sources above — rosemary, sage, yarrow, turmeric, the Artemisia species — are not the material any of this research used. In those oils borneol is a minor to moderate component alongside camphor, cineole and the thujones, and the one study that isolated its contribution did so in a dish, not a person ^{13Reference 13Ehrnhöfer-Ressler MM et al. · 2013In vitroIdentification of 1,8-cineole, borneol, camphor, and thujone as anti-inflammatory compounds in a Salvia officinalis L. infusion using human gingival fibroblasts — in vitroView study →}.

Prevalence in Nature

Borneol splits cleanly into two kinds of source: the few plants that concentrate it almost to purity, and the many aromatic species that carry a few per cent.

The concentrated sources are what the trade is built on. The resin of Dryobalanops aromatica, a Southeast Asian dipterocarp, is the original Borneo camphor. A rare Chinese variant of the camphor laurel, Cinnamomum camphora chvar. borneol, yields an oil so rich in d-borneol that it is farmed for it, and its composition varies substantially with geographic origin, harvest timing, plant part and processing ^{10Reference 10Huang SQ et al. · 2024ReviewHuang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/View study →}. Blumea balsamifera is the source of the l-form ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}.

The diffuse sources are ordinary aromatic herbs, and this is where borneol turns up in a materia medica:

• Rosemary (Salvia rosmarinus) — 0.3–21.0% of the leaf oil across chemotypes, behind 1,8-cineole and camphor ^{11Reference 11Bekhechi A et al. · 2024Chemical variability and anti-inflammatory activity of Rosmarinus officinalis L. leaf essential oil from Algerian SaharaView study →}. The spread is the point: chemotype decides.
• Sage (Salvia officinalis) — a minor oil constituent, and one of the four volatiles carrying the infusion’s anti-inflammatory activity ^{13Reference 13Ehrnhöfer-Ressler MM et al. · 2013In vitroIdentification of 1,8-cineole, borneol, camphor, and thujone as anti-inflammatory compounds in a Salvia officinalis L. infusion using human gingival fibroblasts — in vitroView study →}.
• Yarrow (Achillea millefolium) — one of five principal components (with eucalyptol, camphor, α-terpineol and β-pinene) that together made up 60.7% of the oil in a GC-MS analysis ^{12Reference 12Candan F et al. · 2003In vitroAntioxidant and antimicrobial activity of the essential oil and methanol extracts of Achillea millefolium subsp. millefolium Afan. (Asteraceae) — in vitroView study →}.
• Mugwort (Artemisia vulgaris) — 4.8–8.2% of the leaf oil across two extraction methods, third behind eucalyptol and sabinene, in an oil with documented antimicrobial activity ^{16Reference 16Singh NB et al. · 2023In vitroPhytochemical composition and antimicrobial activity of essential oil from the leaves of Artemisia vulgaris L. — in vitroView study →}.
• Turmeric, wormwood, fringed sage, feverfew, blanketflower and several other Asteraceae and Lamiaceae carry it as a minor volatile alongside camphor and 1,8-cineole.

The pattern across the Asteraceae is consistent enough to be useful: where a plant smells camphoraceous, borneol, camphor, 1,8-cineole and camphene tend to travel together, because they share a biosynthetic neighbourhood.

Discovery & Synthesis

Borneol reached European chemistry as a trade good rather than a discovery. The camphor-like crystalline resin of Dryobalanops aromatica was exported from Borneo for centuries — at times valued above gold — and the molecule kept the island’s name when it was characterised ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}. Chinese medicine had its own long-established supply chains and its own names for the different grades, distinctions that map onto what are now known to be different stereoisomers.

Manufacture today is dominated by the synthetic racemate, made by chemical transformation of camphor or of turpentine oil; isoborneol is its characteristic by-product and the marker quality assays look for ^{5Reference 5Mei Y et al. · 2023Systematic reviewThe history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic reviewView study →}. Natural d-borneol from the Cinnamomum camphora borneol variant is farmed as a premium product ^{10Reference 10Huang SQ et al. · 2024ReviewHuang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/View study →}.

Patents: not yet researched.

Toxicity & Safety

Borneol carries a low flag. It is a long-used topical material with no documented pattern of serious harm at the concentrations used, and the 2017 trial reported it as an effective topical analgesic in a surgical population ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}. The honest caveat is that its safety profile is thinly characterised rather than well established — a point the recent review literature makes about the source oil directly ^{10Reference 10Huang SQ et al. · 2024ReviewHuang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/View study →}.

Safety at a Glance

✅ Low / no toxicity

• A long-established topical material. Used as bingpian for centuries and tested in a randomised placebo-controlled trial of 122 postoperative patients without reported safety problems.
• A borneol-containing drug has been through phase III. Edaravone dexborneol was given as a 14-day infusion to 585 stroke patients in the trial that established its benefit.
• The safety dataset is thin, not clean. No human pharmacokinetics, no repeat-dose toxicology for the isolate; recent reviews describe the safety profile of borneol oil as poorly characterised.
• Opening the blood–brain barrier is not a neutral act. The property that makes borneol useful as an adjuvant also, by definition, admits other circulating substances; the animal work suggests the change is reversible, but it has not been studied in people.
• Know which borneol. d-, l- and synthetic dl-borneol behave differently in absorption and kinetics, and the synthetic form’s activity depended on the dose ratio used.

Full Safety & Interactions Detail

What is established. Topical borneol was well tolerated in the one controlled human trial, in 122 postoperative patients ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}. It is approved in the United States only as a flavouring substance or food adjuvant, a status the trial’s authors flag as out of step with the evidence for topical analgesia ^{1Reference 1Wang S et al. · 2017RCTA clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trialView study →}.

What is not. There is no human pharmacokinetic study, no repeat-dose toxicology package for the isolate, and no genotoxicity assessment characterised here. The 2024 review of Cinnamomum camphora borneol oil states plainly that its safety profile remains poorly characterised and that composition varies with origin, harvest and processing — meaning the material itself is not standardised ^{10Reference 10Huang SQ et al. · 2024ReviewHuang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/View study →}.

The interaction that is the whole point. Borneol’s best-evidenced pharmacological property is that it changes the disposition of other drugs: it inhibits efflux transporters, loosens tight junctions and raises CNS concentrations of co-administered agents in animals ^{2,3Reference 2Zheng Q et al. · 2018Meta-analysisBorneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysisView study →Reference 3Zhang QL et al. · 2017Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeabilityView study →}, and enhances oral absorption of poorly bioavailable saponins in a configuration- and ratio-dependent way ^{8Reference 8Mei Y et al. · 2024AnimalBorneol acts as an adjuvant agent to enhance the oral absorption of Panax notoginseng saponins in rats: effect of optical configuration and compatibility ratios — animalView study →}. Anyone taking a borneol-containing formula alongside a medicine with a narrow therapeutic index is, in principle, taking a pharmacokinetic booster. This has not been studied in humans, which is itself the concern.

Reproductive note. No reproductive-toxicity dataset for isolated borneol is characterised here. Pregnancy and lactation decisions belong to the herb or product page.

Dosage

No oral therapeutic dose has been established for isolated borneol. Its documented human use is topical, and its documented pharmacological role is as an adjuvant inside compound formulae.

These are research figures, not a personal recommendation.

References

1. Wang S, Zhang D, Hu J, et al. (2017). A clinical and mechanistic study of topical borneol-induced analgesia — randomised controlled trial. EMBO Mol Med. https://pubmed.ncbi.nlm.nih.gov/28396565/
2. Zheng Q, Chen ZX, Xu MB, et al. (2018). Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis — meta-analysis. Drug Deliv. https://pubmed.ncbi.nlm.nih.gov/30334462/
3. Zhang QL, Fu BM, Zhang ZJ (2017). Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeability. Drug Deliv. https://pubmed.ncbi.nlm.nih.gov/28687052/
4. Kulkarni M, Sawant N, Kolapkar A, et al. (2021). Borneol: a promising monoterpenoid in enhancing drug delivery across various physiological barriers — review. AAPS PharmSciTech. https://pubmed.ncbi.nlm.nih.gov/33913042/
5. Mei Y, Li L, Fan L, et al. (2023). The history, stereochemistry, ethnopharmacology and quality assessment of borneol — systematic review. J Ethnopharmacol. https://pubmed.ncbi.nlm.nih.gov/36087846/
6. Hu X, Yan Y, Liu W, et al. (2024). Advances and perspectives on pharmacological activities and mechanisms of the monoterpene borneol — systematic review. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/38964157/
7. Liu S, Long Y, Yu S, et al. (2021). Borneol in cardio-cerebrovascular diseases: pharmacological actions, mechanisms, and therapeutics — review. Pharmacol Res. https://pubmed.ncbi.nlm.nih.gov/33892091/
8. Mei Y, Chen Y, Zhang H, et al. (2024). Borneol acts as an adjuvant agent to enhance the oral absorption of Panax notoginseng saponins in rats: effect of optical configuration and compatibility ratios — animal. J Ethnopharmacol. https://pubmed.ncbi.nlm.nih.gov/38734392/
9. Ren J, Hu CL, Zhang ZP, et al. (2019). Development and validation an LC-MS/MS method to quantify (+)-borneol in rat plasma: application to a pharmacokinetic study — animal. J Chromatogr B Analyt Technol Biomed Life Sci. https://pubmed.ncbi.nlm.nih.gov/30743141/
10. Huang SQ, Yi C, Liu XX, et al. (2024). [Chemical composition and pharmacological effects of Cinnamomum camphora chvar. borneol essential oil: a review] — review. Zhongguo Zhong Yao Za Zhi. https://pubmed.ncbi.nlm.nih.gov/39041145/
11. Bekhechi A, Malti CEW, Babali B, et al. (2024). Chemical variability and anti-inflammatory activity of Rosmarinus officinalis L. leaf essential oil from Algerian Sahara. Chem Biodivers. https://pubmed.ncbi.nlm.nih.gov/38388803/
12. Candan F, Unlu M, Tepe B, et al. (2003). Antioxidant and antimicrobial activity of the essential oil and methanol extracts of Achillea millefolium subsp. millefolium Afan. (Asteraceae) — in vitro. J Ethnopharmacol. https://pubmed.ncbi.nlm.nih.gov/12860311/
13. Ehrnhöfer-Ressler MM, Fricke K, Pignitter M, et al. (2013). Identification of 1,8-cineole, borneol, camphor, and thujone as anti-inflammatory compounds in a Salvia officinalis L. infusion using human gingival fibroblasts — in vitro. J Agric Food Chem. https://pubmed.ncbi.nlm.nih.gov/23488631/
14. Luo J, Song W, Yang G, et al. (2015). Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews — systematic review. Am J Chin Med. https://pubmed.ncbi.nlm.nih.gov/25582415/
15. Xu J, Wang A, Meng X, et al. (2021). Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial — randomised controlled trial. Stroke. https://pubmed.ncbi.nlm.nih.gov/33588596/
16. Singh NB, Devi ML, Biona T, et al. (2023). Phytochemical composition and antimicrobial activity of essential oil from the leaves of Artemisia vulgaris L. — in vitro. Molecules. https://pubmed.ncbi.nlm.nih.gov/36903525/

View all 16 references▾